ArticleBMC pulmonary medicine2025
Middle lobe tumors and lymphovascular invasion as independent predictors of recurrence-free survival in stage I NSCLC.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Impact of Lymphovascular Invasion in Resected Pathological Stage I Invasive Non-small Cell Lung Cancer: A Propensity Score-Matched Cohort Study.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrence and metastases are prevalent in lung cancer, contributing to a concerning rate of treatment failure. As a result, there is a pressing need for multivariate analyses of prognostic utility in non-small cell lung cancer (NSCLC). This study reports on the factors influencing metastasis and recurrence-free survival (RFS) in patients with clinical stage I NSCLC who have undergone anatomic lung resection.
methodsThis study included patients diagnosed with stage I NSCLC who received surgical treatment at our institution between January 2016 and December 2022. A careful examination was conducted of the patients' demographic, clinical, radiological, and histopathological data. The prognostic value of the recorded parameters was assessed according to recurrence and/or metastasis, considering RFS during follow-up assessments.
resultsAmong the 616 patients included in this study, the average age was 63 ± 8.9 years, with 506 (82.1%) of patients being male. During a median follow-up period of 50.4 ± 23.7 months (ranging from 1 to 89 months), 79 patients (12.8%) experienced recurrence or metastasis, while 41 patients (6.7%) died. Multivariate analysis showed no significant differences (p > 0.05) regarding recurrence or metastasis development when considering demographic characteristics, tumor size, operation forms, histopathologic types involved, perineural and visceral pleural invasion status, and aspects of oncological treatment. Conversely, the presence of lymphovascular invasion (p < 0.003) and tumor localization in the middle node (p < 0.045) emerged as significant predictors of RFS.
conclusionIn patients with early-stage NSCLC, the presence of lymphovascular invasion and localization of the tumor in the middle lobe are independent predictors of RFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.